Is Heidelberg Pharma AG halal to invest in?

According to Musaffa's Shariah screening methodology, Heidelberg Pharma AG (HPHA.DE) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Heidelberg Pharma AG a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Heidelberg Pharma AG using these criteria to determine its compliance status.

Can Muslims buy shares of Heidelberg Pharma AG?

Muslim investors may consider investing in Heidelberg Pharma AG if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Heidelberg Pharma AG classified as NOT HALAL?

Musaffa determines the Shariah status of Heidelberg Pharma AG by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Heidelberg Pharma AG updated?

The Shariah compliance status of Heidelberg Pharma AG may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Heidelberg Pharma AG become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Heidelberg Pharma AG?

You can check the latest Shariah compliance status of Heidelberg Pharma AG on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Heidelberg Pharma AG HPHA.DE

€2.79

Last Updated: May 15, 12:00 AM·XETRA

HPHA.DE Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: January 16, 2026

Report Source: 2025 3rd Quarter Report

Heidelberg Pharma AG. Stock Analysis HPHA.DE

Germany Health Care Micro Cap Report: Q3, 2025

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

Key Statistics of Heidelberg Pharma AG (HPHA.DE)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€2.70€2.79

Today's Open

€2.79

Volume

355.00

P/E Ratio (TTM)

52 Week Range

€2.33€5.36

Market Cap

132.87M

Avg. Volume

1337.09

Dividend Yield

Financial Metrics & Statements of Heidelberg Pharma AG (HPHA.DE)

FAQ's for Heidelberg Pharma AG (HPHA.DE)

According to Musaffa’s Shariah screening methodology, Heidelberg Pharma AG (HPHA.DE) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.